Intravaginal Prasterone - Clinical Studies (Publications)

# FL Title Author(s) Year
23 1331 - Studies ERC-210,230,231 and 238 Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5 mg intravaginal prasterone for 12 weeks. JSBMB, 159:142-153 Martel, C., Labrie, F., Archer, D.F., Ke, Y., Gonthier, R., Simard, J.N., Lavoie, L., Vaillancourt, M., Montesino, M., Balser, J., Moyneur É. 2016
22 1322 - Study ERC-238 Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator. Gynecol Endocrinol, 32:240-245 Montesino, M., Labrie, F., Archer, D., Zerhouni, J., Côté, I., Lavoie, L., Beauregard, A., Martel, C., Vaillancourt, .M, Moyneur, É., Balser, J. 2016
21 1320 - Study ERC-230 Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study. HMBCI, 25:181-190 Bouchard, C., Labrie, F., Derogatis, L., Girard, G., Ayotte, N., Gallagher, J., Cusan, L., Archer, D., Portman, D., Lavoie, L., Beauregard, A., Côté, I., Martel, C., Vaillancourt, M., Balser, J., Moyneur, É. 2016
20 1319 - Study ERC-238 Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy. J SEX MED, 12:2401-2412 Labrie, F., DeRogatis, L., Archer, D., Koltun, W., Vachon, A., Young, D., Frenette, L., Portman, D., Montesino, M., Côté, I., Parent, J., Lavoie, L., Beauregard, A., Martel, C., Vaillancourt, M., Balser, J., Moyneur, E. et al 2015
19 1318 - Study ERC-230 Serum Steroids Remain Within the Same Normal Postmenopausal Values During 12-Month Intravaginal 0.50% DHEA. Horm Mol Biol Clin Invest, 24:117-129. Ke, Y., Gonthier, R., Simard, J.N., Archer, D., Lavoie, L., Martel, C., Vaillancourt, M. and Labrie, F. 2015
18 1317 - Study ERC-238 Serum Levels of sex steroids and metabolites following 12-weeks of intravaginal DHEA administration. J Ster Biochem Mol Biol. 154:186-196. Ke, Y., Labrie, F., Gonthier, R., Simard, J.N., Bergeron, D., Martel, C., Vaillancourt, M., Montesino, M., Lavoie, L., Archer, D.F., Balser, J., Moyneur, É. et al. 2015
17 1314 - Study ERC-234 Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric, 18:590–607. Bouchard, C., Labrie, F., Archer, D.F., Portman, D.J., Koltun, W., Elfassi, E., Grainger, D.A., Ayotte, N., Cooper, T.A., Martens, M., Waldbaum, A.S., Labrie, C., Côté, I., Lavoie, L., Martel, C., Balser, J. et al. 2015
16 1311 - Study ERC-231 Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause, 22:950-963. Archer, D. F., Labrie, F., Bouchard, C., Portman, D. J., Koltun, W., Cusan, L., Labrie, C., Côté, I., Lavoie, L., Martel, C., Balser, J. 2015
15 1310 - Study ERC-238 Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspereunia and vaginal dryness, symptoms of vulvovaginal atrophy and of the genitourinary syndrome of menopause. Menopause, 23:243-256 Labrie, F., Archer, D. F., Koltun, W., Vachon, A., Young, D., Frenette, L., Portman, D. J., Montesino, M., Côté, I., Parent, J., Lavoie, L., Beauregard, A., Martel, C., Vaillancourt, M., Balser, J., Moyneur, É. et al 2016
14 1309 - Studies ERC-210,230,231 and 234 Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause, Menopause, 22: 1289-1295. Portman, D. J., Labrie, F., Archer, D. F., Bouchard, C., Cusan, L., Girard, G., Ayotte, N., Koltun W., Blouin, F., Young, D., Wade, A., Martel, C. and Dubé, R. 2015
13 1307 - Study ERC-238 Influence of Treatment of Vulvovaginal Atrophy with Intravaginal Prasterone on the Male Partner. Climacteric. 18:817-825 Labrie, F., Montesino, M., Archer, D. F., Lavoie, L., Beauregard, A., Côté, I., Martel, C., Vaillancourt, M., Balser, J., Moyneur, É. et al 2015
12 1304 - Study ERC-230 Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas, 81:46-56. Labrie, F., Archer, D.F., Bouchard, C., Girard, G., Ayotte, N., Gallagher, J.C., Cusan, L., Baron, M., Blouin, F., Waldbaum, A.S., Koltun, W., Portman, D.J., Côté, I., Lavoie, L., Beauregard, A., Labrie, C., Martel, C., Balser, J., Moyneur, E. et al 2015
11 1288 - Study ERC-210 Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. J Sex Med, 11:1766-1785. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Gilbert, L., Martel, C. and Balser, J. 2014
10 1287 - Study ERC-213 Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Ster Biochem Mol Biol, 138:359-367 Labrie F, Martel C, Bérubé R, Côté I, Labrie C, Cusan L, Gomez JL. 2013
9 1254 - Study ERC-210 Intravaginal dehydroepiandrosterone (DHEA, Prasterone), a highly efficient treatment of dyspareunia. Climacteric, 14: 282-288. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, JL., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I, Labrie, C., Lavoie, L., Berger, L., Gilbert, L., Martel, C., Balser, J. 2011
8 1236 - Study ERC-210 Intravaginal DHEA, by a strictly local action, exerts beneficial effects on both vaginal atrophy symptoms and sexual dysfunction. Horm Mol Biol Clin Invest. 4: 499-507 Labrie, F. 2010
7 1235 - Study ERC-210 Effect of intravaginal DHEA in postmenopausal women with vaginal atrophy and pain at sexual activity (dyspareunia) as most bothersome symptom. Proceedings of the 13th World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI), November Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I, Labrie, C., Lavoie, L., Martel, C., Balser, J. 2010
6 1234 - Study ERC-210 High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecological Endocrinology, 26: 524-532. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, JL., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I, Labrie, C., Lavoie, L., Berger, L., Martel, C., Balser, J. 2010
5 1213 - Study ERC-210 Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy, Menopause, 16: 907-922. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Martel, C., Balser, J. 2009
4 1212- Study ERC-210 Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women, Menopause, 16: 923-931. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Balser, J. 2009
3 1211 - Study ERC-210 Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration, Menopause, 16: 897-906. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Martel, C., Balser, J. 2009
2 1190 - Study ERC-213 Corrigendum to: Effect of Intravaginal DHEA on Serum DHEA and Eleven of its Metabolites in Postmenopausal Women. J Steroid Biochem Mol Biol, 112: 169 Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. 2008
1 1189 - Study ERC-213 Effect of Intravaginal DHEA on Serum DHEA and Eleven of its Metabolites in Postmenopausal Women. J Steroid Biochem Mol Biol, 111: 178-194 Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. 2008